60 related articles for article (PubMed ID: 24440960)
1. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
2. Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.
Haberer LJ; McSherry I; Cargill A; McCarthy L
Eur J Clin Pharmacol; 2014 Jan; 70(1):37-45. PubMed ID: 24100471
[TBL] [Abstract][Full Text] [Related]
3. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
[TBL] [Abstract][Full Text] [Related]
5. Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction?
Lehtisalo M; Kiander W; Filppula AM; Deng F; Kidron H; Korhonen M; Sinkko J; Koivula K; Niemi M
Br J Clin Pharmacol; 2023 Jul; 89(7):2309-2315. PubMed ID: 36740817
[TBL] [Abstract][Full Text] [Related]
6. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic drug-drug interaction study between rosuvastatin and emvododstat, a potent anti-SARS-CoV-2 (COVID-19) DHODH (dihydroorotate dehydrogenase) inhibitor.
Morton TL; Laskin OL; Kaushik D; Lee L; Ma J; Kristensen A; O'Keefe K; Golden L; Klein M; Kong R
Pharmacol Res Perspect; 2023 Apr; 11(2):e01076. PubMed ID: 36938928
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Tarkiainen EK; Neuvonen M; Holmberg M; Kiiski JI; Lapatto-Reiniluoto O; Filppula AM; Kurkela M; Backman JT; Niemi M
Clin Pharmacol Ther; 2024 Jan; 115(1):71-79. PubMed ID: 37786998
[TBL] [Abstract][Full Text] [Related]
9. Clinical Analysis and in Vitro Correlation of BCRP-Mediated Drug-Drug Interaction in the Gastrointestinal Tract.
Perera LMB; Okazaki K; Woo Y; Takahashi S; Zhang X; Mizoi K; Takahashi T; Ogihara T
Biol Pharm Bull; 2024; 47(4):750-757. PubMed ID: 38556260
[TBL] [Abstract][Full Text] [Related]
10. Urate transport function of rat sodium-dependent nucleobase transporter 1.
Yasujima T; Murata C; Mimura Y; Murata T; Ohkubo M; Ohta K; Inoue K; Yuasa H
Physiol Rep; 2018 May; 6(10):e13714. PubMed ID: 29845779
[TBL] [Abstract][Full Text] [Related]
11. Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.
Liu ZJ; Deschmann E; Ramsey HE; Feldman HA; Psaila B; Cooper N; Vlachodimitropoulou E; Porter J; Bussel J; Georgieff M; Sola-Visner M
Blood Adv; 2022 Jan; 6(1):13-27. PubMed ID: 34654056
[TBL] [Abstract][Full Text] [Related]
12. Two curcumin analogs inhibited the function and protein expression of breast cancer resistance protein:
Yu CP; Wang YR; Hou YC; Hsieh MT; Li PY; Kuo SC; Lin SP
Xenobiotica; 2023 May; 53(5):454-464. PubMed ID: 37728540
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.
Lescop C; Birker M; Brotschi C; Bürki C; Morrison K; Froidevaux S; Delahaye S; Nayler O; Bolli MH
J Med Chem; 2024 Feb; 67(4):2397-2424. PubMed ID: 38349250
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
16. Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.
Li R; Barton HA; Maurer TS
CPT Pharmacometrics Syst Pharmacol; 2014 Dec; 3(12):e151. PubMed ID: 25494035
[TBL] [Abstract][Full Text] [Related]
17. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
18. Effect of Green Tea and (-)-Epigallocatechin Gallate on the Pharmacokinetics of Rosuvastatin.
Huang S; Xu Q; Liu L; Bian Y; Zhang S; Huang C; Miao L
Curr Drug Metab; 2020; 21(6):471-478. PubMed ID: 32407265
[TBL] [Abstract][Full Text] [Related]
19. Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers.
Kim TE; Ha N; Kim Y; Kim H; Lee JW; Jeon JY; Kim MG
Drug Des Devel Ther; 2017; 11():1409-1416. PubMed ID: 28533679
[TBL] [Abstract][Full Text] [Related]
20. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
Prueksaritanont T; Tatosian DA; Chu X; Railkar R; Evers R; Chavez-Eng C; Lutz R; Zeng W; Yabut J; Chan GH; Cai X; Latham AH; Hehman J; Stypinski D; Brejda J; Zhou C; Thornton B; Bateman KP; Fraser I; Stoch SA
Clin Pharmacol Ther; 2017 Apr; 101(4):519-530. PubMed ID: 27943276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
